Nobivac DHP vaccine for dogs.
Live freeze-dried pellet for suspension for injection.
Each single dose vial contains Canine distemper virus, strain Onderstepoort =104.0 TCID50, Canine adenovirus 2, strain Manhattan LPV3 =104.0 TCID50, Canine parvovirus, strain 154 =107.0 TCID50.
The vaccine contains attenuated antigens to stimulate active immunity in dogs against canine distemper virus, canine parvovirus, infectious canine hepatitis caused by canine adenovirus 1 and respiratory disease caused by canine adenovirus type 2.
For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and viral excretion caused by canine parvovirus infection; to reduce clinical signs of infectious canine hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of respiratory infection and viral excretion caused by adenovirus type 2 infection.
Onset of immunity: one week after vaccination.
Duration of immunity: three years.
Dosage and administration
The contents of one vial of reconstituted vaccine should be injected subcutaneously.
Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of Nobivac Solvent, Nobivac Lepto 2 or Nobivac Rabies.
Sterile equipment should be used for administration.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Primary course vaccination
A single injection should establish active immunity in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose should be given 2–4 weeks later i.e. at 10 weeks of age or older.
To maintain protection a single booster dose is recommended every three years.
The product can be used in pregnant bitches which have previously been vaccinated with Nobivac DHPPi, Nobivac DHP, Nobivac Pi, Nobivac Parvo-C.
Contra-indications, warnings, etc
A common reaction after subcutaneous administration with the diluent provided or the leptospirosis (strain 820K, Ca-12-000) vaccine of the Nobivac series, where this product is authorised, is a diffuse swelling up to 5 mm in diameter at the site of injection. Occassionally this swelling may be hard and painful and last for up to 3 days post injection.
After subcutaneous administration with Nobivac Rabies, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing.
In rare cases a transient rise in body temperature and/or a transient acute hypersensitivity reaction (anaphylaxis) - with signs that may include lethargy, facial oedema, pruritus, dyspnoea, vomiting, diarrhoea or collapse - may occur shortly after vaccination.
Only healthy dogs should be vaccinated. Dogs should not be exposed to unnecessary risk of infection within the first 2 weeks after completion of the vaccination regimen.
While the canine parvovirus vaccine strain may be shed at very low levels for up to 8 days after inoculation, there is no evidence that this results in clinical symptoms if non-vaccinated animals are infected.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except the Nobivac Lepto 2 and/or Nobivac Rabies and/or Nobivac KC. A decision to use Nobivac DHP before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. Do not mix with any other veterinary medicinal product except with Nobivac Solvent, Nobivac Lepto 2 or Nobivac Rabies.
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CDV, CAV2 and CPV that are likely to be encountered under field conditions.
In the case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention and show the package leaflet or the label to the physician.
For animal treatment only. Keep out of reach and sight of children.
Store in a refrigerator (2° C - 8°C). Do not freeze. Protect from light.
Store in a refrigerator at 2° to 8°C. with care being taken to avoid prolonged or repetitive exposure to high ambient temperature following withdrawal from the refrigerator prior to use. Shelf life after reconstitution: 30 minutes.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant, approved for use by the competent authorities.
Nobivac DHP may be presented in cartons containing 5, 10, 25 or 50 single dose vials. Nobivac Solvent (Vm 01708/4148) may be packed together with the vaccine or separately. Not all pack sizes may be marketed.